These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 9382368)

  • 1. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
    Price DT; Ridker PM
    Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oral contraceptives on hemostasis and thrombosis.
    Rosing J; Tans G
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
    Bennet L; Odeberg H
    J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.
    Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I
    Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor V Leiden: should we screen oral contraceptive users and pregnant women?
    Vandenbroucke JP; van der Meer FJ; Helmerhorst FM; Rosendaal FR
    BMJ; 1996 Nov; 313(7065):1127-30. PubMed ID: 8916702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.
    Hellgren M; Svensson PJ; Dahlbäck B
    Am J Obstet Gynecol; 1995 Jul; 173(1):210-3. PubMed ID: 7631684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
    Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
    Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor V Leiden and pulmonary embolism in a young woman taking an oral contraceptive.
    DiSiena MR; Intres R; Carter DJ
    Am J Forensic Med Pathol; 1998 Dec; 19(4):362-7. PubMed ID: 9885932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?
    Spannagl M; Heinemann LA; Schramm W
    Eur J Contracept Reprod Health Care; 2000 Jun; 5(2):105-12. PubMed ID: 10943572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
    Rodeghiero F; Tosetto A
    Ann Intern Med; 1999 Apr; 130(8):643-50. PubMed ID: 10215560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to activated protein C in women using oral contraceptives.
    Spannagl M; Dick A; Assmann A; Heinemann L; Schramm W
    Semin Thromb Hemost; 1998; 24(5):423-30. PubMed ID: 9834008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
    Simkova M; Simko F; Kovacs L
    Bratisl Lek Listy; 2001; 102(5):240-7. PubMed ID: 11725376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to activated protein C in healthy women taking oral contraceptives.
    Olivieri O; Friso S; Manzato F; Guella A; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C
    Br J Haematol; 1995 Oct; 91(2):465-70. PubMed ID: 8547095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
    Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
    Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factor V leiden and venous thromboembolism in a woman taking second generation oral contraceptives: a case report].
    Undas A; Sanak M; Jankowski M; Undas R; Musiał J; Szczeklik A
    Ginekol Pol; 1999 Feb; 70(2):93-7. PubMed ID: 10349814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.